scholarly journals A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial of Partially Hydrolyzed Guar Gum Dietary Fiber for the Improved Gut Microbiome in Healthy Athletes

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1568-1568
Author(s):  
Mahendra Kapoor ◽  
Masaaki Koido ◽  
Mikiko Kawaguchi ◽  
Derek Timm ◽  
Makoto Ozeki
Keyword(s):  
Quality Of Life ◽  
Dietary Fiber ◽  
Relative Abundance ◽  
Gut Microbiome ◽  
Guar Gum ◽  
Controlled Study ◽  
Pcr Analysis ◽  
Rrna Gene ◽  
Partially Hydrolyzed Guar Gum

Abstract Objectives The widespread impact of the gut microbiota in human health has emerged in recent years. Changes in diet and exercise can alter the gut microbiomes of active athletes. We performed a randomized, controlled study to evaluate the relationship between the partially hydrolyzed guar gum (PHGG) prebiotic dietary fiber and the relative abundance of the gut microbiomes in the context of changes in lifestyle-related factors, and their significant correlation with fecal defecation characteristics in healthy athletes. Methods Subjects followed a daily 6 grams dietary intake of either PHGG or placebo for four weeks, following a three weeks washout period, subjects followed another four weeks of crossover alternative administration. Fecal defecation characteristics were assessed using a questionnaire along with the quality of life (QOL) questions and gut microbiome abundance was determined by 16S rRNA gene sequencing and real-time PCR analysis. Results The alteration in gastrointestinal microbiomes relative abundance was correlated to representative changes in fecal defecation characteristics, especially in ameliorating diarrhea (P = 0.035) and fecal excretory feeling (P = 0.038). The PHGG intake led to a significant increase in phylum Actinobacterium (P = 0.04), along with a significant decrease in Bacteroidetes (P = 0.036). A trending decrease in Firmicutes (P = 0.09) Awas noticed. Also, a significant alteration in the relative abundance of Bifidobacterium (P = 0.047) and Clostridium subcluster XI (P = 0.044) were observed with PHGG intake compared with placebo. Principal component analysis and hierarchical clustering analysis represented a clear overview of the distribution of quality of life covariates evaluated in the study. Conclusions Improved diarrhea was associated with the relative abundance of phylum Firmicutes/Bacteroidetes ratio and genera Bacteroides/Prevotella ratio for the PHGG intervention compared to placebo. The finding reveals that even at relatively low dosage, intake of prebiotic PHGG fiber modulates gut microbiomes, and thus improves gastrointestinal health. Overall, the quality of lifestyle factors was significantly improved with PHGG consumption. Funding Sources Taiyo Kagaku, University of Tsukuba, and Otsuma Women's University equally contributed to the study.

HEALTH-RELATED QUALITY OF LIFE(HRQL)IN PATIENTS WITH IBS TREATED WITH PARTIALLY HYDROLYZED GUAR-GUM(PHGG)

2003 ◽  
Vol 98 ◽  
pp. S262 ◽  
Author(s):  
Giancarlo Parisi ◽  
Enrico Bottona ◽  
Maurizio Carrara ◽  
Fabrizio Cardin ◽  
Alessandra Faedo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Guar Gum ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Partially Hydrolyzed Guar Gum

Avascular necrosis of the femoral head: Evaluation of hyperbaric oxygen therapy and quality of life

2020 ◽  
pp. 561-569
Author(s):  
Angeliki Chandrinou ◽  
◽  
Anna Korompeli ◽  
Eirini Grammatopoulou ◽  
Konstantina Gaitanou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Femoral Head ◽  
Avascular Necrosis ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Harris Hip Score ◽  
Controlled Study ◽  
Second Phase

Introduction: The treatment of avascular necrosis of the femoral head (AVNFH) is based on invasive (e.g., core decompression) and non-invasive methods (e.g., hyperbaric oxygen therapy – HBO2). The purpose of the present study is to evaluate the effect of HBO2 on the quality of life (QoL) of patients with AVNFH. Methods: This was a prospective observational non-controlled study of patients with AVNFH treated by HBO2. It was conducted, with the use of Steinberg scale, on 73 patients with AVNFH Stage I or II who were treated with HBO2. Patients’ QoL was assessed with EuroQol-5D-5L (EQ), Harris Hip Score (mHHS), MAHORN (MHOT), and VAS, in three different phases: before HBO2; after the completion of the first phase (20 HBO2 sessions, up to two months); and after the completion of the second phase (20 HBO2 sessions, up to two months after the first phase). A reassessment was made on the completion of each phase. Ratings were also made after the completion of each phase, over the first five months of follow-up. Results: All 73 patients (67.1% males, 32.9% females, mean age: 40.34, SD ± 9.99) participated in the study. Steinberg scale, mean EQ (F (1, 57) = 25.18, η2 = .306 and F (1, 43) = 43.402, η2 = .502); mHHS (F (1, 61) = 67.13, η2 = .524) and F (1, 43) = 31.84, η2 = .425); MHOT (F (1, 61) = 11.68, η2 = .161) and F (1, 43) = 98.01, η2 = .695); and VAS (F (1, 53) = 24.11, η2 = .313) and F (1, 39) = 45.61, η2 = .539), improved between the first and second measurements and between the second and third measurement accordingly (p < .01). Conclusions: HBO2 treatment does not induce alteration of quality of life and is well tolerated and accepted by patients.

scholarly journals Gut Microbiome in a Russian Cohort of Pre- and Post-Cholecystectomy Female Patients

2021 ◽  
Vol 11 (4) ◽  
pp. 294
Author(s):  
Irina Grigor’eva ◽  
Tatiana Romanova ◽  
Natalia Naumova ◽  
Tatiana Alikina ◽  
Alexey Kuznetsov ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Relative Abundance ◽  
Gut Microbiome ◽  
Gallstone Disease ◽  
Illumina Miseq ◽  
Rrna Gene ◽  
Bacterial Phyla ◽  
Female Patients ◽  
Composition And Structure ◽  
Before And After

The last decade saw extensive studies of the human gut microbiome and its relationship to specific diseases, including gallstone disease (GSD). The information about the gut microbiome in GSD-afflicted Russian patients is scarce, despite the increasing GSD incidence worldwide. Although the gut microbiota was described in some GSD cohorts, little is known regarding the gut microbiome before and after cholecystectomy (CCE). By using Illumina MiSeq sequencing of 16S rRNA gene amplicons, we inventoried the fecal bacteriobiome composition and structure in GSD-afflicted females, seeking to reveal associations with age, BMI and some blood biochemistry. Overall, 11 bacterial phyla were identified, containing 916 operational taxonomic units (OTUs). The fecal bacteriobiome was dominated by Firmicutes (66% relative abundance), followed by Bacteroidetes (19%), Actinobacteria (8%) and Proteobacteria (4%) phyla. Most (97%) of the OTUs were minor or rare species with ≤1% relative abundance. Prevotella and Enterocossus were linked to blood bilirubin. Some taxa had differential pre- and post-CCE abundance, despite the very short time (1–3 days) elapsed after CCE. The detailed description of the bacteriobiome in pre-CCE female patients suggests bacterial foci for further research to elucidate the gut microbiota and GSD relationship and has potentially important biological and medical implications regarding gut bacteria involvement in the increased GSD incidence rate in females.

ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study

2008 ◽  
Vol 12 (6) ◽  
pp. 268-275 ◽  
Author(s):  
Aditya K. Gupta ◽  
Richard G. Langley ◽  
Charles Lynde ◽  
Kirk Barber ◽  
Wayne Gulliver ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase Ii ◽  
Life Quality ◽  
Skin Condition ◽  
Controlled Study ◽  
Double Blind ◽  
Plaque Type ◽  
Psoriasis Disability Index ◽  
Stable Plaque

Background: Psoriasis is a chronic skin condition that can negatively affect a patient's quality of life (QoL), often hindering social functioning. ISA247, a novel psoriatic agent, has shown clinical efficacy in moderate to severe psoriasis sufferers, but its effect on QoL is currently not reported. Objective: The objective of this study was to assess the effect of ISA247 on the QoL in patients with stable, plaque-type psoriasis. Methods: A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study assessed the effects of ISA247 doses of 0.5 mg/kg/d ( n = 77) or 1.5 mg/kg/d ( n = 83) compared with placebo ( n = 41) for 12 weeks. QoL was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) scales. Results: ISA247 treatment (pooled groups) significantly improved QoL scores as assessed by both the DLQI and the PDI compared with those receiving placebo ( p < .05). Treatment with the higher dose of 1.5 mg/kg/d demonstrated a significantly greater response to many of the QoL scales compared with the 0.5 mg/kg/d group ( p < .05). Conclusions: ISA247 appears to improve the QoL while also providing effective treatment for chronic, moderate to severe, plaque-type psoriasis.

Sign in / Sign up

Export Citation Format

Share Document